Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.

Mathivet T, Bouleti C, Van Woensel M, Stanchi F, Verschuere T, Phng LK, Dejaegher J, Balcer M, Matsumoto K, Georgieva PB, Belmans J, Sciot R, Stockmann C, Mazzone M, De Vleeschouwer S, Gerhardt H.

EMBO Mol Med. 2017 Dec;9(12):1629-1645. doi: 10.15252/emmm.201607445.

2.

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.

Dejaegher J, Verschuere T, Vercalsteren E, Boon L, Cremer J, Sciot R, Van Gool SW, De Vleeschouwer S.

Int J Cancer. 2017 Nov 1;141(9):1891-1900. doi: 10.1002/ijc.30877. Epub 2017 Jul 19.

PMID:
28681455
3.

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.

Coosemans A, Decoene J, Baert T, Laenen A, Kasran A, Verschuere T, Seys S, Vergote I.

Oncoimmunology. 2015 Dec 21;5(4):e1111505. eCollection 2016 Apr.

4.

Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.

Vandenberk L, Garg AD, Verschuere T, Koks C, Belmans J, Beullens M, Agostinis P, De Vleeschouwer S, Van Gool SW.

Oncoimmunology. 2015 Sep 11;5(2):e1083669. eCollection 2016 Feb.

5.

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.

Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, Agostinis P.

Sci Transl Med. 2016 Mar 2;8(328):328ra27. doi: 10.1126/scitranslmed.aae0105.

PMID:
26936504
6.

The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer.

Baert T, Verschuere T, Van Hoylandt A, Gijsbers R, Vergote I, Coosemans A.

J Immunother Cancer. 2015 Dec 15;3:57. doi: 10.1186/s40425-015-0102-0. eCollection 2015.

7.

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW.

Anticancer Res. 2013 Dec;33(12):5495-500.

PMID:
24324087
8.

Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, Vergote I, Amant F, Van Gool SW.

Anticancer Res. 2013 Sep;33(9):3855-9.

PMID:
24023319
9.

Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.

Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousseyn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, Lefranc F, Van Gool SW, De Vleeschouwer S.

Int J Cancer. 2014 Feb 15;134(4):873-84. doi: 10.1002/ijc.28426. Epub 2013 Sep 4.

10.

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S.

J Neurooncol. 2013 Oct;115(1):9-17. doi: 10.1007/s11060-013-1201-8. Epub 2013 Jul 4.

PMID:
23824536
11.

Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain.

Maes W, Verschuere T, Van Hoylandt A, Boon L, Van Gool S.

Clin Dev Immunol. 2013;2013:952469. doi: 10.1155/2013/952469. Epub 2013 Apr 23.

12.

Galectin-1 in melanoma biology and related neo-angiogenesis processes.

Mathieu V, de Lassalle EM, Toelen J, Mohr T, Bellahcène A, Van Goietsenoven G, Verschuere T, Bouzin C, Debyser Z, De Vleeschouwer S, Van Gool S, Poirier F, Castronovo V, Kiss R, Feron O.

J Invest Dermatol. 2012 Sep;132(9):2245-54. doi: 10.1038/jid.2012.142. Epub 2012 May 24.

13.

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.

Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S.

Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.

PMID:
22527250
14.

Galectin-1 and immunotherapy for brain cancer.

Verschuere T, De Vleeschouwer S, Lefranc F, Kiss R, Van Gool SW.

Expert Rev Neurother. 2011 Apr;11(4):533-43. doi: 10.1586/ern.11.40. Review.

PMID:
21469926
15.

Dendritic cell therapy of high-grade gliomas.

Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S.

Brain Pathol. 2009 Oct;19(4):694-712. doi: 10.1111/j.1750-3639.2009.00316.x. Review.

PMID:
19744041

Supplemental Content

Loading ...
Support Center